Search
Vaccines Treatment Options
A collection of 953 research studies where Vaccines is the interventional treatment. These studies are located in the United States . Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
37 - 48 of 953
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
Active Not Recruiting
This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida +4 locations
Conditions: Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma
Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults
Active Not Recruiting
The goal of this clinical trial is to learn if whole-cell Streptococcus pneumoniae (wSp) vaccination is safe and tolerated in healthy adults. The main aim is to evaluate the safety and tolerability of wSp vaccine.
Researchers will compare wSp vaccinated participants with placebo-treated participants.
Participants will be administered once with 1mg wSp vaccine or placebo. After dosing, they will be followed up for 30 days. In addition to the screening and enrollment visits, each participant wil... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
08/11/2025
Locations: Rochester Clinical Research, Rochester, New York
Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Enrolling By Invitation
This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Recruiting
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2025
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California +29 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Invasive Breast Carcinoma
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Recruiting
The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?
Gender:
ALL
Ages:
12 months and below
Trial Updated:
08/08/2025
Locations: Yale Child Health Research Center, New Haven, Connecticut
Conditions: RSV Infection
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
Recruiting
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/08/2025
Locations: Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia
Conditions: Rotavirus Infections
CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults
Active Not Recruiting
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) for intramuscular administration (IM) in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/08/2025
Locations: Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia
Conditions: Rotavirus Infections
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
Not Yet Recruiting
This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/07/2025
Locations: Diablo Clinical Research, Inc., Walnut Creek, California +1 locations
Conditions: Healthy Participants
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
Recruiting
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/06/2025
Locations: GSK Investigational Site, Lenexa, Kansas +7 locations
Conditions: Urinary Tract Infections
Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.
Completed
The aim of this first time in human proof of concept (FTiH-PoC) study is to evaluate safety and reactogenicity, to demonstrate efficacy and to explore immunogenicity of GlaxoSmithKline's (GSK) Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investigational vaccine compared to placebo (saline).
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/06/2025
Locations: GSK Investigational Site, Washington, District of Columbia +22 locations
Conditions: Sexually Transmitted Diseases
Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines
Completed
This is a prospective, single-site, randomized, then open-label study designed to develop a detailed transcriptional and epigenetic profile of the immune response to pneumococcal vaccination with conjugated and non-conjugated polysaccharide vaccines in the senescent immune system of older adults.
In this study, 40 healthy adults ages 60 and older that have never received pneumococcal vaccination, will be randomized in a 1:1 ratio to receive Prevnar-13 (Pfizer), a conjugated 13-valent vaccine or... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/06/2025
Locations: UConn Center On Aging, Farmington, Connecticut
Conditions: Pneumonia, Aging
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
Recruiting
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults.
Participants will receive either:
* an experimental PG4 vaccine
* a PG4 vaccine comparator
* a standard 20vPnC vaccine comparator
* placebo. A placebo does not have any medicine in it but looks just like the study medicine.
Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to t... Read More
Gender:
ALL
Ages:
Between 65 years and 84 years
Trial Updated:
08/05/2025
Locations: Orange County Research Center, Lake Forest, California +4 locations
Conditions: Streptococcus Pneumoniae
37 - 48 of 953